Tisdag 26 November | 06:47:54 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-26 - Bokslutskommuniké 2024
2024-11-29 - Kvartalsrapport 2024-Q3
2024-10-29 - Extra Bolagsstämma 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning PMDS 0.00 SEK
2024-05-29 - Årsstämma
2024-05-28 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2024-01-31 - Split PMDS 128:1
2023-12-29 - Extra Bolagsstämma 2023
2023-11-28 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-06-27 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning PMDS 0.00 SEK
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-29 - Kvartalsrapport 2022-Q3
2022-08-30 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning PMDS 0.00 SEK
2022-05-17 - Årsstämma
2022-05-17 - Kvartalsrapport 2022-Q1
2022-02-16 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning PMDS 0.00 SEK
2021-05-27 - Årsstämma
2021-05-27 - Extra Bolagsstämma 2021
2021-05-27 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-24 - Kvartalsrapport 2020-Q3
2020-08-25 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning PMDS 0.00 SEK
2020-05-26 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-18 - Bokslutskommuniké 2019
2019-11-22 - Kvartalsrapport 2019-Q3
2019-10-22 - Extra Bolagsstämma 2019
2019-08-27 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning PMDS 0.00 SEK
2019-05-21 - Årsstämma
2019-05-21 - Kvartalsrapport 2019-Q1
2019-02-26 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-20 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning PMDS 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-06 - Bokslutskommuniké 2017
2017-11-21 - Kvartalsrapport 2017-Q3
2017-08-30 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
PMD Device Solutions utvecklar och säljer medicinska produkter för andningsövervakning, för både sjukhus och hemvård. Dess primära produkt är RespiraSense, en lösning som används för att övervaka andningsfrekvensen och stödja upptäckten av patientförsämring, och för att undvika andningssvikt och ogynnsamma patientresultat. RespiraSense kommersialiseras i Europa, Storbritannien och är FDA godkänd i USA.
2024-08-16 23:15:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

PMD Device Solutions AB (”PMDS” or the "Company") publishes today an information memorandum (the ‘’Memorandum’’) in connection with the Company’s forthcoming rights issue of shares of approximately SEK 27.5 million, which was announced by the Company on June 11, 2024, and resolved by the Company’s board of directors on July 5, 2024 (the ”Rights Issue”). The subscription period for the Rights Issue runs between August 19 – September 2, 2024. The Memorandum is available on the Company’s website, www.pmd-solutions.com, and on Nordic Issuing AB’s website, www.nordic-issuing.se.

The Memorandum, the application for subscription of shares with and without subscription rights and other information about the Rights Issue are available on the Company's website, www.pmd-solutions.com, and on Nordic Issuing AB's website www.nordic-issuing.se. The record date for receiving subscription rights was August 15, 2024. The subscription period for the Rights Issue runs between August 19 – September 2, 2024.

Timetable for the Rights Issue, all dates referring to 2024:
https://investors.pmd-solutions.com/en/rights-issue-2024/

August 19 – September 2The Subscription Period for the Rights Issue.
August 20 – August 28Trading with subscription rights on Nasdaq First North Growth Market.
August 20Trading with BTA commences. Trading continues until the Rights Issue has been registered with the Swedish Companies Registration Office, estimated to occur in week 38, 2024.
Around September 5The announcement of the outcome of the Rights Issue is expected to be published.

Full terms and conditions of the Rights Issue and other information about the Company are provided in the Memorandum.

Advisors
Stockholm Corporate Finance AB is acting as financial adviser to the Company in the Rights Issue. Eversheds Sutherland Advokatbyrå AB is acting as the legal adviser to the Company. Nordic Issuing AB is the issuing agent in the Rights Issue.

IMPORTANT INFORMATION
This press release is not an offer to subscribe for shares in PMDS and investors should not subscribe or acquire any securities. Invitation to concerned persons to subscribe for shares in PMDS will only be made through the Memorandum published by the Company.

This press release shall not, directly or indirectly, be released, published or distributed in or to the United States, Australia Japan, Canada, New Zealand, Hong Kong, South Africa or other country where such action as a whole or in part is subject to legal restrictions. Neither subscription rights, shares subscribed for ("BTA") or newly issued shares have been recommended or approved by any US federal or state securities authority or regulatory authority. No subscription rights, BTA or newly issued shares have been registered or will be registered under the United States Securities Act of 1933, as applicable, or in accordance with applicable laws in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or in any other country where the Rights Issue or distribution of the press release is in violation of applicable laws or regulations or presupposes that a further prospectus is established, registered or that any other measure is undertaken beyond that required by Swedish law. The press release, as well as the prospectus, the application form and other documents attributable to the Rights Issue, may consequently not be distributed to any such jurisdiction.

There is no intention to register any portion of the offer in the United States and the securities issued in the Rights Issue will not be offered to the public in the United States.
The Company has not authorized any offer to the public with regards to the shares or rights that are referred to in this communication in any member state of the European Economic Area (''EEA'') besides Sweden. This communication is only addressed to and is only directed at qualified investors in other members states within the EEA.

This press release may contain certain forward-looking information that reflects PMDS’ current views on future events as well as financial and operational development. Words that are "intended", "come", "judged", "expected", "can", "plan", "appreciate" and other expressions that imply indications or predictions about future developments or trends, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future performance or development and actual outcomes may differ substantially from what is stated in forward-looking information. This information, the opinions and the forward-looking statements contained in this press release are valid only on this date and may be amended without notice. PMDS makes no representations about publishing updates or revisions of forward-looking information, future events or similar circumstances other than the applicable law.